Ann: Quarterly Activities and Cashflow Report, page-27

First 27 Last

Share
Profile

Follow
matchbox20

12,709 Posts.

266

03/02/20

11:37

Post #: 42713305
Share

Originally posted by Pan head ↑

"OPERATIONAL UPDATE - THE TECHNION

During the Q1FY period Cann Global through its Research Division, MCRG, invested approximately $1.1M towards the Research on Multiple Sclerosis being undertaken by the Technion Haifa in Israel, headed by Professor Meiri. We have been particularly pleased with the ongoing significant successes in our medical research to find a cure and treatment of Multiple Sclerosis, using unique strains and formulations of cannabis, being undertaken by the Technion University in Haifa, Israel, where this past year has seen mice trials successfully undertaken and with extremely promising results, following our earlier successes last year in vitro. The results to date have identified unique formulations from particular cannabis strains which either successfully halted the progression of the disease or assisted in recovery. The Company believes that each of these results individually, and the potential combination of both of these formulations in treatment, has the potential to be ground-breaking. This now leads us to human trials which are currently being coordinated in Israel together with Israel’s leading hospitals. In discussions with the Technion team, the Company is expecting, should the human trials succeed over the coming year, that we may be able to have a formulation for a product for distribution which we anticipate should help millions worldwide suffering from this debilitating condition."

I must admit I'm a little surprised that this doesn't recive more attention.
For me this is biggest part of the report.

I admit I would like more information on the human trails but at this stage It would be too risky for the company and the team at Technion to share any information about procedures and stats.
Because medical cannabis is already an approved drug once this blend of strains has been proven to work the company can get straight into production and sale.
If successfull and as good as the company is suggesting this drug is a game changer.

Expand

So which one is it.
Last Q,and trials on patients being monitored by leading Isreali hospitals
ThisQ,This now leads us to human trials

CGB Price at posting: 1.5¢ Sentiment: None Disclosure: Not Held
3 Upvote

0 Great analysis

Reply

Top Stories

ADH

Adairs MD and CEO steps down after 17 years in company management

FEG

China's Xingye snags 19.99% stake in Far East Gold, eyeing latter's Indonesian gold play

SRN

Copper and zinc zone prove exciting news for Surefire close to WA's Yidby

DEL

Delorean unlocks $30M through Tanarra finance facility for bioenergy projects

Is the ASX getting its groove back? Here's 5 IPOs in September to watch